Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast version of Five Must-Know Things: Merck & Co. tells Scrip oncology will remain a key priority; J&J is responsibly cautious on growth; Takeda pays big for HutchMed drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

More from Business

More from Scrip